IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. - Libura, Marta; Bialopiotrowicz, Emilia; Giebel, Sebastian; Wierzbowska, Agnieszka; Roboz, Gail J.; Piatkowska-Jakubas, Beata; Pawelczyk, Marta; Gorniak, Patryk; Borg, Katarzyna; Wojtas, Magdalena; Florek, Izabella; Matiakowska, Karolina; et al. (Scientific Reports, 2021)